2,6-disubstituted piperiddines as modulators
    3.
    发明授权
    2,6-disubstituted piperiddines as modulators 失效
    2,6-二取代的哌啶作为调节剂

    公开(公告)号:US07410961B2

    公开(公告)日:2008-08-12

    申请号:US10586765

    申请日:2005-01-14

    摘要: The present invention is further directed to compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R16, R17, R18, R19, R20, R21 and R22 are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

    摘要翻译: 本发明还涉及式(I)的化合物:其中R 1,R 2,R 3,R 4, R 5,R 6,R 7,R 8,R 9,R 9, R 10,R 16,R 17,R 18,R 19,R 16, R 20,R 21,R 22和R 22如本文所定义),其是趋化因子受体活性的调节剂,并且可用于 预防或治疗某些炎性和免疫调节性疾病和疾病,过敏性疾病,特应性病症,包括过敏性鼻炎,皮炎,结膜炎和哮喘,以及自身免疫病态如类风湿性关节炎和动脉粥样硬化。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及趋化因子受体的疾病中的用途。

    Amino heterocyclic modulators of chemokine receptor activity
    10.
    发明授权
    Amino heterocyclic modulators of chemokine receptor activity 失效
    趋化因子受体活性的氨基杂环调节剂

    公开(公告)号:US07700772B2

    公开(公告)日:2010-04-20

    申请号:US10589406

    申请日:2005-02-08

    摘要: Compounds of Formula I and Formula II: (wherein n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, R19, R24, R25, R26, R27, R28, R29, R30, R33, R34, R35, R36, R37, R38, A, j, k, m, n, X, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

    摘要翻译: 式I和式II化合物(其中n,R1,R2,R3,R4,R5,R6,R7,R8,R9,R10,R15,R16,R17,R18,R19,R24,R25,R26, R28,R29,R30,R33,R34,R35,R36,R37,R38,A,j,k,m,n,X,Y和Z如本文所定义),其是趋化因子受体活性的调节剂, 预防或治疗某些炎性和免疫调节性疾病和疾病,过敏性疾病,特应性病症,包括过敏性鼻炎,皮炎,结膜炎和哮喘,以及自身免疫性病态如类风湿性关节炎和动脉粥样硬化。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及趋化因子受体的疾病中的用途。